Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands |
3 Months Ended |
6 Months Ended |
12 Months Ended |
Apr. 30, 2018 |
Apr. 30, 2017 |
Apr. 30, 2018 |
Apr. 30, 2017 |
Oct. 31, 2017 |
| Cash flows from operating activities: |
|
|
|
|
|
| Net loss |
$ (13,174)
|
$ (13,238)
|
$ (17,357)
|
$ (26,923)
|
|
| Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
| Share-based compensation |
|
|
1,378
|
2,226
|
|
| Loss from change in fair value of embedded derivatives |
|
|
45
|
25
|
|
| Depreciation |
|
|
4,302
|
4,296
|
|
| Non-cash interest expense on preferred stock and debt obligations |
|
|
2,845
|
2,958
|
|
| Unrealized foreign exchange gains |
|
|
(367)
|
(259)
|
|
| Deferred income taxes |
|
|
(3,035)
|
0
|
|
| Project asset impairment |
|
|
485
|
0
|
|
| Other non-cash transactions, net |
|
|
203
|
241
|
|
| Decrease (increase) in operating assets: |
|
|
|
|
|
| Accounts receivable |
|
|
24,379
|
(9,020)
|
|
| Inventories |
|
|
30,981
|
(1,779)
|
|
| Other assets |
|
|
(1,382)
|
(366)
|
|
| Increase (decrease) in operating liabilities: |
|
|
|
|
|
| Accounts payable |
|
|
3,290
|
(4,837)
|
|
| Accrued liabilities |
|
|
(4,238)
|
(5,684)
|
|
| Deferred revenue |
|
|
386
|
547
|
|
| Net cash provided by (used in) operating activities |
|
|
41,915
|
(38,575)
|
|
| Cash flows from investing activities: |
|
|
|
|
|
| Capital expenditures |
|
|
(5,506)
|
(8,290)
|
|
| Project asset expenditures |
|
|
(21,749)
|
(10,154)
|
|
| Cash acquired from asset acquisition |
|
|
0
|
633
|
|
| Net cash used in investing activities |
|
|
(27,255)
|
(17,811)
|
|
| Cash flows from financing activities: |
|
|
|
|
|
| Repayment of debt |
|
|
(10,919)
|
(6,299)
|
|
| Proceeds from debt |
|
|
13,091
|
17,891
|
|
| Payment of deferred financing costs |
|
|
(352)
|
(119)
|
|
| Payment of preferred dividends and return of capital |
|
|
(2,096)
|
(2,067)
|
|
| Cash received for common stock issued for stock plans |
|
|
0
|
50
|
|
| Proceeds from sale of common stock and warrant exercises, net |
|
|
3,268
|
12,785
|
|
| Net cash provided by financing activities |
|
|
2,992
|
22,241
|
|
| Effects on cash from changes in foreign currency rates |
|
|
87
|
(38)
|
|
| Net increase (decrease) in cash, cash equivalents and restricted cash |
|
|
17,739
|
(34,183)
|
|
| Cash, cash equivalents and restricted cash-beginning of period |
|
|
87,448
|
118,316
|
$ 118,316
|
| Cash, cash equivalents and restricted cash-end of period |
$ 105,187
|
$ 84,133
|
105,187
|
84,133
|
$ 87,448
|
| Supplemental cash flow disclosures: |
|
|
|
|
|
| Cash interest paid |
|
|
1,144
|
2,821
|
|
| Noncash financing and investing activity: |
|
|
|
|
|
| Common stock issued for Employee Stock Purchase Plan in settlement of prior year accrued employee contributions |
|
|
0
|
50
|
|
| Net noncash reclass of project assets to inventory |
|
|
11,740
|
0
|
|
| Assumption of debt in conjunction with asset acquisition |
|
|
0
|
2,289
|
|
| Acquisition of project assets |
|
|
0
|
2,386
|
|
| Series C preferred share conversions |
|
|
15,598
|
0
|
|
| Accrued purchase of fixed assets, cash paid in subsequent period |
|
|
273
|
1,816
|
|
| Accrued purchase of project assets, cash paid in subsequent period |
|
|
$ 1,504
|
$ 115
|
|